Slide 1: | CORBUSPHARMA.COM
NASDAQ:CRBP | CORBUSPHARMA.COM
Slide 2: Highlights
HIGHLIGHTS + First in patient study n=85 CFTR mutation agnostic + Primary endpoint achieved with acceptable safety and tolerability * Reduction of multiple lung inflammatory cells and mediators * Clinical benefit seen in acute pulmonary exacerbations * Data support further clinical development
Slide 3: Trial Design
TRIAL DESIGN ens:
Slide 4: JBT101-CF-001 Phase 2 Trial Design
JBT101-CF-001 PHASE 2 TRIAL DESIGN Double-blind, randomized, placebo-controlled, 16-week trial + Supported by a $5MM Development 21 clinical sites in the US, UK, Germany, Italy, and Poland Assia — ee Adults ages 18 to 65 with cystic fibrosis (CF) + Designed with the CFF Therapeutic Eligibility crite
Slide 5: Anabasum Trial Design
ANABASUM TRIAL DESIGN Randomization prior to Visit 1 + Al subjects randomized 2:2:3 to Cohorts 1, 2, and 3 for Days 1-28 + Cohorts | and 2 randomized 1:1 Cohorts 4 and 5 for Days 29-84 + Cohort 3 randomized 1:1:4 to Cohorts 4, 5 and 6 for Days 29-84 i te = Tir dose Increase in dose 1 { Coton: soT-10
Slide 6: Objectives
OBJECTIVES Ce fresolution|receptors in immune system Primary Objective + Evaluate safety and tolerability Secondary / Exploratory Objectives + Evaluate plasma concentrations and metabolites + Evaluate efficacy using FEV1, lung clearance index, aadee and CFQ-R + Evaluate blood and sputum biomarkers o
Slide 7: Primary Endpoint: Safety and Tolerability Outcomes
PRIMARY ENDPOINT: SAFETY AND TOLERABILITY OUTCOMES Safety + Treatment-emergent adverse events * Changes in vital signs, laboratory safety testing, electrocardiograms, Addiction Research Center Inventory — Marijuana questionnaire (ARCI-M) Events of special interest: + Acute pulmonary exacerbations re
Slide 8: Sample Size
SAMPLE SIZE Safety * 25 subjects in a treatment group yields 2 95% probability of detecting adverse events that occur at a true rate of 12% or higher Efficacy * 25 subjects within an active group and 20 subjects within the placebo group yields 80% power to detect a statistically significant differen
Slide 9: Subject Disposition and Baseline Characteristics
SUBJECT DISPOSITION AND BASELINE CHARACTERISTICS is:
Slide 10: Study Populations
STUDY POPULATIONS 89 Randomized 4 withdrew prior to dosing >| + 3withdrew consent + 1 pulmonary exacerbation Safety and Efficacy Populations N=85 23 Completed 51 Completed plaeebs treatment anabasum treatment
Slide 11: Withdrawals from the Study in Safety Population
10 WITHDRAWALS FROM THE STUDY IN SAFETY POPULATION Subjects, n (%) Weeks 1-4 Weeks 5-12 Status Anabasum | Placebo | Anabasum Placebo N=50 N=35 N=61 N=24 Withdrew consent 0 0 2(3.3) 0 Adverse event 1 (2.0) 1 (2.9) 3(4.9) 0 Lost to follow-up 1 (2.0) 0 0 0 Other 1 (2.0) 0 1(1.6) 0
Slide 12: Baseline Demographics of Subjects
BASELINE DEMOGRAPHICS OF SUBJECTS Weeks 1-4 Weeks 5-12 Characteristic Anabasum | Anabasum | Placebo | Anabasum | Anabasum | Placebo 1mgQp 5mgQD 20mgQd | 20mg BID N=26 N=24 N=35 N=31 N=30 N=24 Male, % 65.4 50.0 48.6 516 50.0 62.5 ‘Age, mean (range) 26.9 (19-52) | 28.8 (18-62) | 29.2(18-59) | 28.5 (18
Slide 13: Baseline Disease Characteristics of Subjects
2 BASELINE DISEASE CHARACTERISTICS OF SUBJECTS Weeks 1-4 Weeks 5-8 Characteristic Anabasum | Anabasum | Placebo | Anabasum | Anabasum | Placebo imgqp | SmgQo 20mgQp | 20mgBID N=26 N=24 N=35 N=31 N=30 N=24 BAA 14/73 zaAo/a Ta/2/s 20/713 17 FS08D: 2alleles/ Lalleles/O alleles | sorsrassesasse | sax/20
Slide 14: Baseline Medications of Subjects
BASELINE MEDICATIONS OF SUBJECTS Subjects, n (%) Medication Anabasum Anabasum Placebo Anabasum Anabasum Placebo 1mgaQp 5mgQD 20 mg QD 20 mg BID N=26 N=24 N=35 N=31 N=30 N=24 Azithromycin 8 (30.1) 16 (66.7) 21 (60.0) 14 (45.2) 13 (43.3) 14 (58.3) Inhaled or oral prophylactic 12 (46.2) inhaled 10 (41.
Slide 15: Baseline Demographics and Characteristics: Conclusions
BASELINE DEMOGRAPHICS AND CHARACTERISTICS: CONCLUSIONS + Baseline demographics and disease characteristics are similar among treatment groups + Differences are minor among treatment groups in gender distribution, previous number of acute pulmonary exacerbations in the last year, CFQ-R Respiratory Sy
Slide 16: Plasma Concentrations
= PLASMA CONCENTRATIONS ens:
Slide 17: Anabasum Plasma Concentrations
16 ANABASUM PLASMA CONCENTRATIONS ‘Anabasum, ng/mL + SD Anabasum Cmax Plasma concentration was measured 3 + 0.5 hours after the first dose of 1 mg, 5 mg, or 20 mg and compared to those in healthy human volunteers. 1000 eer101-croo1 (9 Healthy Humans 10 as ‘Anabasum Single Dose, mg 20 25 + The anabas
Slide 18: Safety Results: Treatment-Emergent Adverse Events
17 SAFETY RESULTS: TREATMENT-EMERGENT ADVERSE EVENTS easy
Slide 19: Subjects with Treatment Emergent Adverse Events by Dose
19 SUBJECTS WITH TREATMENT EMERGENT ADVERSE EVENTS BY DOSE Subjects, n (%) ‘Treatment-emergent Weeks 1-4 Weeks 5-12 Post Treatment. Adi Event (TEAE) ‘Anabasum| Anabasum| Placebo | Anabasum| Anabasum] Placebo | Anabasum| Anabasum| Placebo amg 5mg 20mg 20 mg BID 20mg 20 mg BID N=26 N=24 N=35 N=3t N=30
Slide 20: Subjects with Treatment-Emergent Adverse Events: Serious Adverse Events
19 SUBJECTS WITH TREATMENT-EMERGENT ADVERSE EVENTS SERIOUS ADVERSE EVENTS Anabasum Placebo * 6 pulmonary exacerbations + 7 pulmonary exacerbations + 1 hand fracture + 1 thrombosis in device + No increase in pulmonary exacerbations with anabasum treatment + No serious adverse event was assessed as re
Slide 21: Subjects with TEAEs by Maximum Severity and Weeks
SUBJECTS WITH TEAEs BY MAXIMUM SEVERITY AND WEEKS ‘Subjects with TEAES ‘Weeks 1-4 Weeks 5-12 Post Treatment Weeks 13-16 System ‘Anabasum] Anabasum] Placebo | Anabasum] Anabasum| Placebo | Anabasum| Anabasum| — Post 1mg 5mg 20mg | 20mg BID 20mg | 20mgBID| Placebo N=26 N=24 N=35 N=31 N=30 N=24 N=32 N=
Slide 22: Number of TEAEs by Maximum Severity and Weeks
NUMBER OF TEAEs BY MAXIMUM SEVERITY AND WEEKS Subjects with TEAEs Weeks 14 Weeks 5-12 Post Treatment Weeks 13-16 Sem ‘Anabasum| Anabasum] Placebo | Anabasum] Anabasum] Placebo | Anabasum| Anabasum| Post img sme 20mg 20 mg BID 20mg 20 mg BID Placebo N=26 N=24 N=35 N=31 N=30 N=24 N=31 N=30 N=24 Tota|
Slide 23: Treatment-Emergent Adverse Events Leading to Discontinuation from Study
TREATMENT-EMERGENT ADVERSE EVENTS LEADING TO DISCONTINUATION FROM STUDY 5 Adverse Events + 3related to study drug as assessed by the site investigator + Decrease in focus for 4 hours after taking drug: Mild, intermittent, D4-15 — placebo discontinued D10, study discontinued D37 + Lack of cognitive c
Slide 24: Subjects with TEAEs by System
SUBJECTS WITH TEAEs BY SYSTEM ‘Subjects with TEAEs, n(%) Weeks 1-4 Weeks 5-13 System ‘Anabasum | Anabasum | p).¢949 | Anabasum | Anabasum | 1 on5 1mg Smg ees 20 mg 20mg BID me N=26 N=24 N=31 N=30 Total number of TEAEs 23 25 30 59 49 24 Total number of subjects with any TEAE 14(53.8) | 13(542) | 15(4
Slide 25: TEAEs in Subjects in Any Group During Active Treatment
24 TEAEs IN 2 2 SUBJECTS IN ANY GROUP DURING ACTIVE TREATMENT Subjects with TEAEs Weeks 1-4 Weeks 5-13 System Anabasum | Anabasum Anabasum | Anabasum img 5mg fees 20 mg 20 mg BID he N=26 N=24 N=31 N=30 Total number of TEAEs 23 25 30 59 49 24 Total number of subjects with any TEAE 14 (53.8) 13 (54.2)
Slide 26: Hematology Laboratory Investigations
HEMATOLOGY LABORATORY INVESTIGATIONS Data are shown for combined anabasum 20 mg QD and 20 mg BID subjects (N = 58) and placebo subjects (N = 22) from baseline at Visit 3 when subjects start on these doses B li Change from baseline Investigation | Treatment Mean (SD) Mean (SD) Week 12 Week 16 . Anaba
Slide 27: Clinical Chemistry Laboratory Investigations
CLINICAL CHEMISTRY LABORATORY INVESTIGATIONS Data are shown as change from baseline for combined anabasum 20 mg QD and 20 mg BID subjects (N = 58) and placebo subjects (N = 22) from baseline when subjects start on these doses . Change from baseline Investigation Treatment Wear (58 Mean (SD) Week 12
Slide 28: Acute Pulmonary Exacerbations
27 ACUTE PULMONARY EXACERBATIONS easy
Slide 29: Acute Pulmonary Exacerbations
ACUTE PULMONARY EXACERBATIONS Requirement for new antibiotics Symptoms
Slide 30: Acute Pulmonary Exacerbation Requiring Treatment with Intravenous Antibiotics
ACUTE PULMONARY EXACERBATION REQUIRING TREATMENT WITH INTRAVENOUS ANTIBIOTICS Captured as an event of special interest. Assignment to treatment arm is by time of onset of symptoms that required intravenous antibiotic treatment ‘Treatment Group ents weetsia | Weelesa2 cebo, N= 35 38H) Anabasum 1 mg,
Slide 31: First Acute Pulmonary Exacerbation Defined as Treatment with New Antibiotics
FIRST ACUTE PULMONARY EXACERBATION DEFINED AS TREATMENT WITH NEW ANTIBIOTICS Abroader look at acute pulmonary exacerbations as defined by treatment with new antibiotics for respiratory system sympte ymproms First Acute Pulmonary Exacerbations Subjects nv at isk () (Any New Antibiotic) Per Year ‘Trea
Slide 32: FEV1
31 FEV1 ens:
Slide 33: FEV1 Percent Predicted Values
FEV1 PERCENT PREDICTED VALUES LS Mean Change (SE) from Baseline Weeks 1-12 10 Placebo Value ‘Treatment 8 seme Anabasum 2000 g uo quem Anabasum 20 mg BID FeV1 Placebo, N = 24 3 5 % predicted z 3 Anabasum 20 mg, N= 31 $8 25 Anabasum20mgBI0.N=30| 622 | 8 £ ° Cs xo 3 s “2.5 RO EO 5s 8 Ss 75 4 40 1 29 85
Slide 34: Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Symptoms Score
CYSTIC FIBROSIS QUESTIONNAIRE-REVISED (CFQ-R) RESPIRATORY SYMPTOMS SCORE Weeks 1-12 LS Mean Difference (SE) from Baseline An increase in score means fewer symptoms = 10 Placebo tanaline 2 —Arabasum 20 Value Treatment ‘Mean (range) 8 a Be eH Ba o 7. Gor Placebo, N= 24 Lege! 2 Respiratory z (339-889)
Slide 35: Sputum Biomarkers: Inflammatory Cells and Mediators
34 SPUTUM BIOMARKERS INFLAMMATORY CELLS AND MEDIATORS ens:
Slide 36: Inflammatory Cells in CF Sputum at Baseline
36 INFLAMMATORY CELLS IN CF SPUTUM AT BASELINE Baseline Value, Mean (SD), 1019 Treatment, N Total cells | Neutrophils | Eosinophils |Macrophages| Lymphocytes Fiecobe 6.92(0.76) | 6.72(0.88) | 2.47(2.64) | 5.54(0.76) | 1.00(1.98) — 20mg 6.88 (0.56) | 6.66 (0.66) | 4.61(1.66) | 5.42(0.64) | 1.44 (2.34
Slide 37: Anabasum Reduces Inflammatory Cells in CF Sputum (1)
ANABASUM REDUCES INFLAMMATORY CELLS IN CF SPUTUM (1) Least Squares (LS) mean difference from placebo, 10g49 (SE) Total Cells Neutrophils Eosinophils Reduced Cell Numbers Reduced Cell Numbers Reduced Cell Numbers 1mg a aad ime pa oo Be 1mg img 5mg Smg Smg Smeg 20 mg 20m 20 mg 20 mg 20 mg BID 20m 20 m
Slide 38: Anabasum Reduces Inflammatory Cells in CF Sputum (2)
ANABASUM REDUCES INFLAMMATORY CELLS IN CF SPUTUM (2) Least Squares (LS) mean difference from placebo, logio (SE) Lymphocytes Macrophages Reduced Cell Numbers Reduced Cell Numbers 14mg Ame img 5mg Sime Sime 20mg 20me 20me 20 mg BID 20mg 810 20mg 810 25 2 45 1 05 0 05 1 15-125 41 075 05 025 0 Ls Mean
Slide 39: Inflammatory Mediators in CF Sputum at Baseline
INFLAMMATORY MEDIATORS IN CF SPUTUM AT BASELINE Baseline Value Treatment, N Mean (SD), 10949 Interleukin-8 Neutrophil elastase | Immunoglobulin G fea, 5.17 (0.43) 2.02 (0.63) 4.49 (0.50) Aeon 20mg 5.06 (0.48) 2.04 (0.59) 1.36 (0.60) Avena 20g BID 5.22 (0.45) 2.19 (0.50) 1.59 (0.50) Subjects in diffe
Slide 40: Anabasum Reduces Inflammatory Mediators in CF Sputum
ANABASUM REDUCES INFLAMMATORY MEDIATORS IN CF SPUTUM Least Squares (LS) mean difference from placebo, logio (SE) Interleukin-8 Neutrophil Elastase Immunoglobulin G < Reduced Mediators € Reduced Mediators Reduced Mediators 41mg ame — Ame Ame 5mg Sime Sig Sime 20mg 20mg 20m 20mg p=0.033 p=0.061 p=0037
Slide 41: Blood Biomarkers: Inflammatory Cells and Mediators
40 BLOOD BIOMARKERS INFLAMMATORY CELLS AND MEDIATORS ens:
Slide 42: Blood Biomarkers of Inflammation at Baseline
BLOOD BIOMARKERS OF INFLAMMATION AT BASELINE Baseline Value Mean (SD), logig N=28 Treatment, N Interleukin-8, pg/ml C-reactive protein, nmol/L] Immunoglobulin G, g/L Placebo Neos 1.51 (0.10) 1.48 (0.60) 1.13 (0.14) Anebasum 201mg 4.53 (0.08) 4.47 (0.39) 1.10 (0.16) Anabesum 20 mg BID 1.58 (0.19) 1.4
Slide 43: Effect of Anabasum on Inflammatory Mediators in Blood
EFFECT OF ANABASUM ON INFLAMMATORY MEDIATORS IN BLOOD Least Squares (LS) mean difference from placebo, logig (SE) Interleukin-8 CRP Immunoglobulin G Reduced Mediators < Reduced Mediators < Reduced Mediators 14mg img Lime pox Aime 5mg 01 5me Sime ooo Sime 20mg o1 20mg 20m, fou 20mg 20mg BID 3 201mg B
Slide 44: Conclusions
43 CONCLUSIONS * Patients were exposed to anabasum at the C,,,, levels targeted « Anabasum showed evidence of biologic activity in the lungs with reduction of multiple inflammatory cells and mediators * Safety and tolerability profiles were acceptable * Promising evidence of clinical benefit was see
Slide 45: Thank You!
45 Thank You! We are Very Grateful to: The participants who took part in our Phase 2 clinical study of anabasum Our clinical investigators for their commitment to working with patients to complete the study Our employees for their tireless work and dedication to make this study possible The Cystic F
Slide 46: Contact Us
45 CONTACT US Corbus Pharmaceuticals Holdings, Inc. 617.963.0100 info@corbuspharma.com www.corbuspharma.com 100 River Ridge Drive Norwood, MA 02062